Rhovac is open to all sale and partnership opportunities

The biotech company Rhovac has yet again initiated plans for a potential transaction – or a partnership. According to CEO Anders Månsson, the company is "ready for everything."

BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

All paths are open when it comes to the biotech company Rhovac's journey foward. That is, as long as the results of the ongoing phase IIb trial with its lead candidate, RV001, which is a RhoC-based cancer vaccine, look promising, CEO at Rhovac Anders Månsson tells MedWatch.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Rhovac hires investment bank to generate interest in lead candidate
For subscribers
IO Biotech begins phase III trial with partner MSD
For subscribers
Sanofi pays up to USD 1bn for new multiple myeloma therapy
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO

The former chairman of the Novo Nordisk Foundation, Sten Scheibye, however, says that he does not recognize this interpretation.

For subscribers

Søren Nielsen, CEO of hearing aid company Demant. | Foto: Demant / Pr

Hearing health

Jyske Bank questions Demant's continued momentum

For subscribers

Pharma & biotech

Leo acquisition negotiated with four suitors while struggling to survive

For subscribers

Pharma & biotech

Jefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concerns

For subscribers

Pharma & biotech

Media: Issues at Novo Nordisk factory have been known for more than a year

For subscribers

Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA notice for a Novo Nordisk factory in the US, says media outlet Fiercepharma. | Foto: Novo Nordisk/pr

Pharma & biotech

Media: This is why the FDA has reprimanded Novo Nordisk following US plant inspection

For subscribers

European trade association calls for comprehensive reform of MDR and IVDR
Medtech Europe considers EU regulations to be unpredictable, complex and slow.
For subscribers
Third time's the charm: Novo Nordisk makes new bid to get obesity drug reimbursed in Danish home market
In a new and narrowed application for public reimbursement for the obesity drug Wegovy, Novo Nordisk aims to cover only ”a limited group.” However, the company will not disclose who this includes.
For subscribers
Novo Holdings completes acquisition of US antibiotics company for DKK 3.2bn
The acquisition of Paratek Pharmaceuticals is Novo Holdings’ largest single investment in antimicrobial resistance treatments to date.
For subscribers
Novo Nordisk and UNICEF extend joint initiative to combat childhood obesity
As part of the extended agreement, Novo Nordisk will invest USD 8m over the next three years.
For subscribers
Board member appointed as new CEO of Orphazyme
The biotech company prepares new activities.
For subscribers
Eli Lilly sues clinics for selling fake diabetes drug
Novo Nordisk was also out in force in June.
For subscribers

Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO

The former chairman of the Novo Nordisk Foundation, Sten Scheibye, however, says that he does not recognize this interpretation.

For subscribers

Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

EU Health Commissioner Stella Kyriakides has received an open letter from trade association Medtech Europe and 34 national organizations. | Foto: Julien Warnand/AP/Ritzau Scanpix

Other

European trade association calls for comprehensive reform of MDR and IVDR

Medtech Europe considers EU regulations to be unpredictable, complex and slow.

For subscribers

Pharma & biotech

Media: Issues at Novo Nordisk factory have been known for more than a year

Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)

For subscribers

Pharma & biotech

Media: This is why the FDA has reprimanded Novo Nordisk following US plant inspection

Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.

For subscribers

Hearing health

Jyske Bank questions Demant's continued momentum

With increasing competition in the hearing aid market, Jyske Bank analyst Janne Vincent Kjær does not expect Demant to continue its strong momentum into 2024.

For subscribers